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Pediatric Milk-based Efavirenz Freeze-dried Nanoemulsion:
Formulation and Characterization
• Approximately 1.8 million children under 15 years of age are living with HIV (c.2017)
• Pediatric patients with HIV have been lagging behind adults in receiving anti-retroviral
therapy (ART) due to numerous barriers, one of which being the lack of appropriate
pediatric anti-retroviral (ARV) drug formulations
• Efavirenz (EFV) is an HIV-1 specific and a first choice anti-retroviral in adults and
pediatric pharmacotherapy
• The available efavirenz formulations for pediatric patients older than 3 months are
Sustiva tablet (600 mg) and capsule (50 mg, 200 mg)
• These formulations are “Pediatric” not necessarily “Pediatric friendly”
• Therefore, there is a need to formulate a product that is easy to administer to pediatric
patients and contains natural and minimum excipients
• The freeze-dried efavirenz o/w nanoemulsion contains milk as the aqueous phase,
medium chain triglyceride as the oil phase and span 80 was added to improve the
homogeneity of the nanoemulsion
• The efavirenz freeze-dried powder will be suitable to administer by dissolving in water
or milk-based drinks or sprinkled on food for oral administration in pediatric patients
three months of age or older.
Introduction
Methods
Drug yield:
Table: 1 Drug content
Batch 1 Batch 2 Batch 3 Average
98.4% 96.7% 105.3% 100.2%
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Powder X-Ray Diffraction
Fig 3(a) shows that the drug is crystalline in nature whereas 3(b) shows that the  
freeze-dried formulation is amorphous
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Thermogravimetric Analysis 
The 3 batches of freeze-dried powder showed an average of 1.16% desolvation mass loss 
below 150 °C 
Table: 2 Particle size distribution of EFV freeze-dried reconstituted 
nanoemulsion (d.nm) 
Sample name Z-Ave PDI D(n)10 D(n)50 D(n)90
Batch 1 663.5 0.605 294 381 505
Batch 2 618.6 0.490 281 364 478
Batch 3 526.8 0.562 69.6 89.4 244
Accelerated Stability Study
Table: 3 Accelerated Drug Stability 
Drug yield: 6 days
Batch 1 Batch 2 Batch 3 Average
97.8% 90.8% 94.9% 94.5%
Drug yield: 17 days
89.5% 104.9% 95.6% 96.7%
Particle size (Z-average): 6 days
604.9 561.8 576.1 580.93
Particle size (Z-average): 17 days
597.1 442.6 502.0 513.9
Powder flow studies
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• Aqueous phase: non-fat milk + water
• Oil phase: Efavirenz + MCT + span 80
• An oil/water emulsion was formed
Pre-mixing using a 
homogenizer
• The particle size of the emulsion was reduced 
to form a nanoemulsionUltrasonication
• The nanoemulsion was freeze-dried for ~ 40 
hours to form the final formualtionFreeze-drying
Objective
• To formulate a freeze-dried nanoemulsion with particle size less than 1000 nm
• To assess drug yield of the freeze-dried powder
• To determine stability of freeze-dried powder 
• To characterize powder flow property for the freeze-dried formulation
• To characterize crystallinity of the freeze-dried formulation
• To determine the moisture content of the freeze-dried formulation
Results
R² = 0.9995
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Fig 1: Calibration curve
Fig 4 (a): Pure efavirenz drug Fig 4 (b): Freeze-dried powder
Fig 3: Thermogravimetric analysis of 3 batches of freeze-dried powder
Fig 2: HPLC analysis of freeze-dried powder Conclusion
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Hypothesis
A milk based freeze-dried nanoemulsion of efavirenz  with a stable drug content  and a z-
average of less than 1000 nm can be prepared
The angle of repose was determined to understand the
flow of the freeze-dried powder. It was calculated using
the following USP formula:
tan(α)=height/0.5 base
= 62.5 degrees
Fig 5: Angle of repose experiment
• An amorphous final powder formulation was obtained by freeze-drying the nanoemulsion
• Drug yield obtained was within the FDA limit of 90-110%
• The powder could be reconstituted with water to give a nanoemulsion with mean 
hydrodynamic diameter less than 1000 nm
• The freeze-dried powder showed an average of 1.16% mass loss below 150°C 
• There was no significant difference in the drug content from day 0 to day 17; p-value was 
0.4983 > 0.05
• The stability testing results showed that the particle size was less than 1000 nm
• According to the USP <1174>, the powder flow was ‘very poor’
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Characterization of freeze-dried formulation
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